HSBC set a €87.00 ($101.16) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research report sent to investors on Tuesday morning. The brokerage currently has a buy rating on the stock.

Other analysts also recently issued research reports about the stock. Credit Suisse Group set a €75.00 ($87.21) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a report on Friday, December 7th. JPMorgan Chase & Co. set a €85.90 ($99.88) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a report on Wednesday, February 27th. Berenberg Bank set a €88.65 ($103.08) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a report on Tuesday, March 5th. Commerzbank set a €79.00 ($91.86) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a report on Friday, December 7th. Finally, Sanford C. Bernstein set a €98.00 ($113.95) target price on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a report on Friday, December 7th. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of €82.68 ($96.14).

Shares of ETR:FME opened at €69.68 ($81.02) on Tuesday. The stock has a market capitalization of $21.38 billion and a PE ratio of 10.80. The company has a current ratio of 1.25, a quick ratio of 0.96 and a debt-to-equity ratio of 58.49. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of €55.44 ($64.47) and a fifty-two week high of €91.74 ($106.67).

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Article: What causes a recession?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.